Innoviva, Inc.
INVANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $411.3M | $358.7M | $310.5M | $331.3M | $391.9M | $336.8M |
| Operating income | $163.7M | $166.9M | $113.9M | — | $375.1M | $321.1M |
| Net income | $271.2M | $23.4M | $179.7M | $220.3M | $368.8M | $293.8M |
| Total assets | $1.64B | $1.30B | $1.24B | $1.23B | $926.4M | $999.6M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $1.17B | $691.2M | $675.0M | $565.8M | $414.7M | $539.9M |
| EPS (diluted) | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 | $2.02 |
| Shares out. | 62.7M | 63.2M | 68.1M | 69.6M | 101.4M | 101.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 39.8%
- Net margin
- 65.9%
- Return on equity
- 23.1%
- Return on assets
- 16.6%
- Return on capital (ROCE)
- 10.3%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $18.71
- Revenue growth (YoY)
- 14.7%
- Net income growth (YoY)
- 1059.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 4.5%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Portfolio Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Renaissance Technologies LlcPassive (13G)Feb 12, 2026
- Dimensional Fund Advisors LpPassive (13G)Jan 21, 2026
- Bank Of Nova ScotiaPassive (13G)Oct 8, 2025
- Franklin Resources IncPassive (13G)Aug 5, 2025
- Blackrock, Inc.Passive (13G)Apr 28, 2025
- Sarissa Capital Management LpActivist (13D)Mar 17, 2025
- Westfield Capital Management Co LpPassive (13G)Feb 11, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Basso StephenOfficer — Chief Financial Officer | May 15, 2026 | Grant | 1,123 | $0.00 |
| Raifeld PavelOfficer — Chief Executive Officer | May 15, 2026 | Grant | 1,123 | $0.00 |
| Zhen MarianneOfficer — Chief Accounting Officer | May 20, 2026 | Tax withholding | 1,127 | $22.24 |
| Linden JosephineDirector | May 18, 2026 | Grant | 5,733 | $0.00 |
| Dipaolo MarkDirector | May 4, 2026 | Grant | 9,786 | $0.00 |
| Raifeld PavelOfficer — Chief Executive Officer | May 4, 2026 | Grant | 126,646 | $0.00 |
| Zhen MarianneOfficer — Chief Accounting Officer | May 4, 2026 | Grant | 12,766 | $0.00 |
| Schlesinger Sarah J.Director | May 4, 2026 | Grant | 9,786 | $0.00 |
| Basso StephenOfficer — Chief Financial Officer | May 4, 2026 | Grant | 37,994 | $0.00 |
| Small Derek ADirector | May 4, 2026 | Grant | 9,786 | $0.00 |
| Haimovitz JulesDirector | May 4, 2026 | Grant | 9,786 | $0.00 |
| Basso StephenOfficer — Chief Financial Officer | Feb 20, 2026 | Tax withholding | 1,244 | $23.39 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.4M | 9.6 | +1.8% |
| Apr 30, 2026 | 6.3M | 11.3 | -6.6% |
| Apr 15, 2026 | 6.7M | 11.3 | +2.8% |
| Mar 31, 2026 | 6.5M | 7.1 | -4.0% |
| Mar 13, 2026 | 6.8M | 10.9 | +2.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 18, 2026
- Results of operationsMay 6, 2026
- Shareholder voteMay 4, 2026
- Results of operationsFeb 25, 2026
- Results of operationsNov 5, 2025
- Results of operationsAug 6, 2025
- Shareholder voteMay 21, 2025
- Results of operationsMay 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.